% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Enssle:301337,
      author       = {J. Enssle$^*$ and T. Brinkschmidt$^*$ and R. Dürrwald and
                      S. Wolf$^*$ and D. Zurmeyer and B. Steffen$^*$ and E.
                      Ullrich$^*$ and T. Oellerich$^*$ and H. Serve$^*$ and I. von
                      Metzler$^*$},
      title        = {{I}mmune responses after one versus two {I}nfluenza {A}/{B}
                      vaccinations in patients with multiple myeloma.},
      journal      = {Annals of hematology},
      volume       = {104},
      number       = {5},
      issn         = {0939-5555},
      address      = {New York},
      publisher    = {Springer},
      reportid     = {DKFZ-2025-01003},
      pages        = {2813-2821},
      year         = {2025},
      note         = {2025 May;104(5):2813-2821},
      abstract     = {Seasonal Influenza A/B vaccination is routinely
                      administered in patients with Multiple Myeloma (MM) given
                      their disease-and therapy-associated immunosuppression and
                      risk of infection. Previous data show poor seroconversion
                      rates after one vaccination with an increase to ~ $60\%$
                      after boosting while the impact of multiple lines of therapy
                      remains unclear. Accordingly, we performed a retrospective
                      single-center study assessing immune responses after single
                      or prime-boosting vaccination in 71 patients with MM treated
                      at our institution during the 2019/20 season. Overall,
                      $63.3\%$ of patients with MM achieved sufficient responses
                      after one or two Influenza A/B vaccinations. In patients
                      receiving a prime-boost approach, significantly higher
                      serological titers but no significant increase in responder
                      rates were observed after the boost vaccination. Complete or
                      very good partial remission and no immunoparesis were
                      identified as independent predictors of sufficient
                      serological response by multivariate regression analysis and
                      responders were characterized by high CD19+ B-cell and CD4+
                      T-cell counts. Patients achieving a sufficient response only
                      after the prime-boost approach showed significantly shorter
                      time since high-dose chemotherapy and autologous stem-cell
                      transplantation (HDC-ASCT). Together, this study suggests
                      that single vaccination against Influenza A/B might be
                      sufficient for patients with MM while a prime-boost approach
                      might be necessary for patients with recent HDC-ASCT.},
      keywords     = {Influenza A/B (Other) / Multiple myeloma (Other) /
                      Serological and immune cell response (Other) / Vaccination
                      (Other)},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40372494},
      doi          = {10.1007/s00277-025-06367-1},
      url          = {https://inrepo02.dkfz.de/record/301337},
}